Management of coronary artery disease in patients with type 2 diabetes mellitus

被引：14

作者：

Srikanth S. ^{[1
]}

Deedwania P. ^{[1
]}

机构：

[1] Veterans Affairs Central California Health Care System, University of California-San Francisco Program at Fresno, Fresno, CA 93703

来源：

Current Cardiology Reports | 2007年 / 9卷 / 4期

关键词：

Percutaneous Coronary Intervention; Coronary Artery Bypass Graft; Atorvastatin; Fenofibrate; Abciximab;

D O I：

10.1007/BF02938374

中图分类号：

学科分类号：

摘要：

Diabetes mellitus is as much a vascular disease as it is a metabolic disorder. The metabolic abnormalities associated with diabetes include hyperglycemia, and abnormal carbohydrate, fat, and protein handling. These abnormalities increase oxidative stress and activate the renin angiotensin system, which subsequently causes endothelial dysfunction and predisposes to atherosclerosis. Type 2 diabetes has reached epidemic proportions and because of its strong association with coronary artery disease (CAD), it is responsible for increasing cardiovascular morbidity and mortality in the United States. In this article we review some of the evidence and the rationale for comprehensive risk reduction to prevent and treat CAD in individuals with diabetes mellitus. The comprehensive risk reduction strategy includes lifestyle changes, glycemic control, and control of dyslipidemia and hypertension. Advances in revascularization techniques, and superior outcomes of coronary artery bypass grafting as an interventional modality over percutaneous coronary intervention, are discussed. We also identify controversies and issues that currently remain unresolved. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：264 / 271

页数：7

共 39 条

[1]

Hu G., Jousilahti P., Katoh S., Tuomilehto J., Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction, Diabetologia, 48, pp. 856-861, (2005)

[2]

Yusuf S., Hawken S., Ounpuu S., Et al., Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study, Lancet, 364, pp. 937-952, (2004)

[3]

Standards of medical care in diabetes: 2006, Diabetes Care, 29, SUPPL. 1, (2006)

[4]

Huxley R., Barzi F., Woodward M., Excess risk of fatal coronary heart disease associated with diabetes in men and women: Meta-analysis of 37 prospective cohort studies, BMJ, 332, pp. 73-78, (2006)

[5]

Turner R.C., Millns H., Neil H.A., Et al., Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Knigdom Prospective Diabetes Study (UKPDS: 23), BMJ, 316, pp. 823-828, (1998)

[6]

The Diabetes Control and Complications (DCCT) Research Group, Kidney Int, 47, pp. 1703-1720, (1995)

[7]

Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association Diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe, Lancet, 354, pp. 617-621, (1999)

[8]

Chiasson J.L., Josse R.G., Gomis R., Et al., Acarbose for prevention of T2DM: The STOP-NIDDM randomized trial, Lancet, 359, pp. 2072-2077, (2002)

[9]

Stettler C., Allemann S., Juni P., Et al., Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials, Am Heart J, 152, pp. 27-38, (2006)

[10]

Baigent C., Keech A., Kearney P.M., Et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins, Lancet, 366, pp. 1267-1278, (2005)

← 1 2 3 4 →